Bayer raises full-year earnings guidance on pharmaceutical growth
FROM THE WIRE · FINANCE.YAHOO.COM
Bayer lifts full-year earnings guidance as third-quarter pharmaceutical sales climb 8% on Nubeqa and Kerendia, while impairments hold the quarter at a net loss and a Roundup settlement awaits court approval. SINGAPORE, SG / ACCESS Newswire / November 13, 2026 / Bayer raises its…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishThe guidance upgrade driven by pharmaceuticals can support the stock and the healthcare sector.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Third-quarter pharmaceutical sales climbed 8% to $5.2 billion.
- 02Shares rose more than 5% on the day of the release.
- 03Group EBITDA guidance was raised by $222 million.
NEWS IMPACT AND MARKET REACTIONChange from the reference price
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets